Belgium's UCB to sell China neurology, allergy business for $680 mln
Acquisition includes anti-allergy medicines Zyrtec and Xyzal
Deal expected to close in fourth quarter
UCB to focus on innovation and partnerships
Adds context in paragraph 7, advisers in final paragraph
By Geert De Clercq and Yantoultra Ngui
PARIS/SINGAPORE, Aug 26 (Reuters) -UCB UCB.BR, a Belgian biopharmaceutical firm, said on Monday it would sell its Chinese neurology and allergy business to Singapore-based asset management group CBC and Abu Dhabi sovereign investor Mubadala for $680 million.
The deal includes UCB's neurology portfolio comprising drugs like Keppra, Vimpat and Neupro, and anti-allergy medicines Zyrtec and Xyzal, commonly used to treat watery eyes and runny noses.
The Brussels-listed firm will also sell a manufacturing site in Zhuhai city.
UCB said in a statement there would be no impact on its forecast for 2024 and the deal was expected to close in the fourth quarter.
"In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China," UCB CEO Jean-Christophe Tellier said.
The deal will allow the company to focus its efforts on innovation and partnerships, ensuring its strategic goals align with the evolving demands of the Chinese market, it said.
Some of the biggest global drugmakers, undeterred by mounting Sino-U.S. tensions, are scouring for deals in China to replenish drug pipelines and boost their presence in the world's second-biggest pharmaceutical market, industry executives and investment bankers have said.
"The demand for central nervous system products in China has been increasing over the past decade," CBC CEO Fu Wei said.
"This strategic deal aligns with CBC's strategy of investing in high-potential companies with quality products, strong brand equity, dedicated talents and steady growth outlook," he added.
CBC is Asia's largest healthcare-focused asset management firm with assets under management of $8.8 billion, according to the statement.
The deal adds to CBC and Mubadala's partnership. The Abu Dhabi-based investor in October last year invested in CBC's APG-backed Chinese life-science real estate investment platform.
In April 2023, CBC and Mubadala were the lead investors in a $315 million fundraising round for Chinese biopharma company Hasten.
UCB's shares have jumped 104% year-to-date, giving it a market value of $34.8 billion on Monday, according to LSEG data.
Lazard is the financial adviser to UCB with Freshfields Bruckhaus Deringer as the legal adviser. PJT Partners is the financial adviser to CBC and Mubadala with Clifford Chance as legal adviser, the statement showed.
Reporting by Geert De Clercq in Paris and Yantoultra Ngui in Singapore; Editing by Tassilo Hummel, Sonia Cheema and Jamie Freed
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
